GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Plus Therapeutics Inc (STU:XMP0) » Definitions » Policy Acquisition Expense

Plus Therapeutics (STU:XMP0) Policy Acquisition Expense


View and export this data going back to . Start your Free Trial

What is Plus Therapeutics Policy Acquisition Expense?

Policy Acquisition Expense only applies to insurance companies.


Plus Therapeutics Business Description

Traded in Other Exchanges
Address
2710 Reed Road, Suite 160, Houston, TX, USA, 77051
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).